Switch theme
Sign up to access all valuation multiples
Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.
2021
1.8K+
LTM Revenue $936M
LTM EBITDA $404M
$8.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Giant Biogene has a last 12-month revenue (LTM) of $936M and a last 12-month EBITDA of $404M.
In the most recent fiscal year, Giant Biogene achieved revenue of $707M and an EBITDA of $320M.
Giant Biogene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Giant Biogene valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $936M | XXX | $707M | XXX | XXX | XXX |
| Gross Profit | $767M | XXX | $580M | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | $404M | XXX | $320M | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 45% | XXX | XXX | XXX |
| EBIT | $389M | XXX | $295M | XXX | XXX | XXX |
| EBIT Margin | 42% | XXX | 42% | XXX | XXX | XXX |
| Net Profit | $341M | XXX | $263M | XXX | XXX | XXX |
| Net Margin | 36% | XXX | 37% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Giant Biogene's stock price is HKD 71 (or $9).
Giant Biogene has current market cap of HKD 72.7B (or $9.3B), and EV of HKD 66.3B (or $8.5B).
See Giant Biogene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.5B | $9.3B | XXX | XXX | XXX | XXX | $0.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Giant Biogene has market cap of $9.3B and EV of $8.5B.
Giant Biogene's trades at 12.0x EV/Revenue multiple, and 26.4x EV/EBITDA.
Equity research analysts estimate Giant Biogene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Giant Biogene has a P/E ratio of 29.5x.
See valuation multiples for Giant Biogene and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.3B | XXX | $9.3B | XXX | XXX | XXX |
| EV (current) | $8.5B | XXX | $8.5B | XXX | XXX | XXX |
| EV/Revenue | 9.8x | XXX | 12.0x | XXX | XXX | XXX |
| EV/EBITDA | 22.8x | XXX | 26.4x | XXX | XXX | XXX |
| EV/EBIT | 23.7x | XXX | 28.7x | XXX | XXX | XXX |
| EV/Gross Profit | 12.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 29.5x | XXX | 35.2x | XXX | XXX | XXX |
| EV/FCF | 37.6x | XXX | 37.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGiant Biogene's last 12 month revenue growth is 30%
Giant Biogene's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Giant Biogene's rule of 40 is 80% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Giant Biogene's rule of X is 118% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Giant Biogene and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 30% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 45% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 37% | XXX | XXX | XXX |
| Rule of 40 | 80% | XXX | 75% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 118% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Giant Biogene acquired XXX companies to date.
Last acquisition by Giant Biogene was XXXXXXXX, XXXXX XXXXX XXXXXX . Giant Biogene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Giant Biogene founded? | Giant Biogene was founded in 2021. |
| Where is Giant Biogene headquartered? | Giant Biogene is headquartered in Hong Kong. |
| How many employees does Giant Biogene have? | As of today, Giant Biogene has 1.8K+ employees. |
| Who is the CEO of Giant Biogene? | Giant Biogene's CEO is Mr. Jianya Yan. |
| Is Giant Biogene publicy listed? | Yes, Giant Biogene is a public company listed on HKG. |
| What is the stock symbol of Giant Biogene? | Giant Biogene trades under 02367 ticker. |
| When did Giant Biogene go public? | Giant Biogene went public in 2022. |
| Who are competitors of Giant Biogene? | Similar companies to Giant Biogene include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Giant Biogene? | Giant Biogene's current market cap is $9.3B |
| What is the current revenue of Giant Biogene? | Giant Biogene's last 12 months revenue is $936M. |
| What is the current revenue growth of Giant Biogene? | Giant Biogene revenue growth (NTM/LTM) is 30%. |
| What is the current EV/Revenue multiple of Giant Biogene? | Current revenue multiple of Giant Biogene is 9.8x. |
| Is Giant Biogene profitable? | Yes, Giant Biogene is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Giant Biogene? | Giant Biogene's last 12 months EBITDA is $404M. |
| What is Giant Biogene's EBITDA margin? | Giant Biogene's last 12 months EBITDA margin is 43%. |
| What is the current EV/EBITDA multiple of Giant Biogene? | Current EBITDA multiple of Giant Biogene is 22.8x. |
| What is the current FCF of Giant Biogene? | Giant Biogene's last 12 months FCF is $245M. |
| What is Giant Biogene's FCF margin? | Giant Biogene's last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Giant Biogene? | Current FCF multiple of Giant Biogene is 37.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
